Measuring the impact of a formulary decision: Conversion to one quinolone agent

Formulary

Volumn 31, Issue 10, 1996, Pages 906-914

  Bowman, Gerald K ^a   Moleski, Ron ^b   Mangi, Richard J ^b  

^a HOSPITAL OF SAINT RAPHAEL   (United States)

^b Hospital of Saint Raphael

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005540838     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hatoum HT, Vlasses PH. Patient outcome and the future practice of pharmacy DICP Ann Pharmacother 1991; 25:208-10.
2. Belliveau P. Ofloxacin vs ciprofloxacin: A comparison. Conn Med 1992;56:261-3.
3. Walker RC, Wright AJ. The fluoroquinolones. Mayo Clin Proc 1991;66:1249-59.
4. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94
5. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy 1993;13(Suppl):4S-17S
6. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2:378-424.
7. Janknegt R. Fluoroquinolones - Use of clinical data to aid formulary choice by the system of objective judgement analysis (SOJA) method. Pharmacoeconomics 1994;6:15-33.
8. Gentry LO. Prescribing considerations in fluoroquinolone therapy. Pharmacotherapy 1993;13(Suppl):39S-44S.
9. Nightingale CH. Pharmacokinetic considerations in quinolone therapy. Pharmacotherapy 1993;13(Suppl):34S-38S.
10. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990,34:40-3.
11. Dekker AW, Rozenberg-Arksa M, Verhoef J. Infection prophylaxis in acute leukemia: A comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 1987;106:7-12.
12. Smith SM, Eng RH. Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985;27:688-91.
13. Roush MK, Dupuis RE. Significance of the ciprofloxacin-antacid interaction (DIAS Rounds). DICP Ann Pharmacother 1991;25:473-5.
14. Fang G, Brennan C, Wagener M, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: Prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991;35:1849-55.
15. Frost RW, Lasseter KC, Noe, AJ, et at. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992;36-830-32.
16. Lettieri JT, Rogge MC, Kaiser L, et al. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992;36:993-6.
17. Allon M, Lopez EJ, Kyung-Whan Min. Acute renal failure due to ciprofloxacin Arch Intern Med 1990;150:2187-9.
18. Rastogi S, Atkinson JL, McCarthy JT Allergic nephropathy associated with ciprofloxacin. Mayo Clin Proc 1990,65: 987-9.
19. Day CA, Marceau-Day, Day DF. Increased susceptibility of Pseudomonas aeruginosa to ciprofloxacin in the presence of vancomycin. Antimicrob Agents Chemother 1993,37:2506-8.
20. Dan M, Golomb J, Gorea A. Concentration of ciprofloxacin in human prostatic tissue after oral administration Antimicrob Agents Chemother 1986;30:88-9.
21. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients, Antimicrob Agents Chemother 1993; 37:1073-81.
22. Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989;96:528-37
23. Fabre D, Bressolle F, Gomeni R, et al. Steady state pharmacokinetics of ciprofloxacin from patients with nosocomial pneumonia: Penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991;35:2521-5.
24. Gasser TC, Ebert SC, Graversen PH, et al. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother 1987;31:709-12.
25. Licitra CM, Brooks RG, Sieger BE. Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection. Antimicrob Agents Chemother 1987,31:805-7.
26. Drusano GL, Weit M, Forrest A, et al. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother 1987;31: 860-4.
27. Davis RL, Koup JR, Williams-Warren J, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987,31:915-9.
28. Todd PA, Faulds D. Ofloxacin- A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991;42:825-76.
29. Flor S, Guay DR, Opsahl JA, et al. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother 1990;34:2436-8.
30. Gentry LO, Rodriguez-Gomez G Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991;35:538-41.
31. Guay DR, Opsahl JA, McMahon FG, et al. Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrob Agents Chemother 1992;36.308-12.
32. DuPont HL, Ericsson CD, Mathewson JJ, et al Five versus three days of ofloxacin therapy for traveler's diarrhea: A placebo-controlled study. Antimicrob Agents Chemother 1992;36:87-91.
33. Hooton TM, Batteiger BE, Judson FN, et al. Ofloxacin versus doxycycline for treatment of cervical infection with Chlamydia trachomatis. Antimicrob Agents Chemother 1992;36:1144-6.
34. Malik IA, Abbas Z, Karim, M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients Lancet 1992;339:1092-6.
35. Flor SC, Rogge MC, Chow AT Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Antimicrob Agents Chemother 1993;37: 1468-72.
36. Lehto P, Kivisto KT. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1994;38:248-51.
37. Israel D, Gillum JG, Turik M, et al. Pharrnacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1993;37:2193-9.
38. Navarro AS, Cabarga MM, Jurle AD. Oral absorption of ofloxacin administered together with aluminum. Antimicrob Agents Chemother 1994;38:2510-12.
39. Bitar N, Claes R, Van der Auwera P. Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob Agents Chemother 1989;33:1686-90.
40. Outman WE. Nightingale CH Metabolism and the fluoroquinolones Am J Med 1989;87(Suppl 6C) 37S-42S.
41. Wijnandis GJ, Vree TB, Janssen TJ, et al. Drug-drug interactions affecting fluoroquinolones. Am J Med 1989,87(Suppl 6C):47S-51S.
42. Raoof S, Wollschlager C, Kahn FA. Ciprofloxacin increases serum levels of theophylline. Am J Med 1987;82(Suppl 4A). 115-18
43. Rubenstein, Segev S. Drug interactions of ciprofloxacin with other non-antibiotic agents. Am J Med 1987;:82(Suppl 4A):119-23.
44. Stocks JM, Wallace RJ, Griffith DE, et al. Ofloxacin in community-acquired lower respiratory infections. Am J Med 1989;87(Suppl 6C).52S-56S.